TriazolamCAS# 28911-01-5 |
- Gemcitabine HCl
Catalog No.:BCC1076
CAS No.:122111-03-9
- Trovafloxacin mesylate
Catalog No.:BCC3931
CAS No.:147059-75-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 28911-01-5 | SDF | Download SDF |
PubChem ID | 5556 | Appearance | Powder |
Formula | C17H12Cl2N4 | M.Wt | 343.21 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in DMSO | ||
Chemical Name | 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine | ||
SMILES | CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4Cl | ||
Standard InChIKey | JOFWLTCLBGQGBO-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Triazolam Dilution Calculator
Triazolam Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.9137 mL | 14.5683 mL | 29.1367 mL | 58.2734 mL | 72.8417 mL |
5 mM | 0.5827 mL | 2.9137 mL | 5.8273 mL | 11.6547 mL | 14.5683 mL |
10 mM | 0.2914 mL | 1.4568 mL | 2.9137 mL | 5.8273 mL | 7.2842 mL |
50 mM | 0.0583 mL | 0.2914 mL | 0.5827 mL | 1.1655 mL | 1.4568 mL |
100 mM | 0.0291 mL | 0.1457 mL | 0.2914 mL | 0.5827 mL | 0.7284 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 3,7,16-Trihydroxystigmast-5-ene
Catalog No.:BCN5191
CAS No.:289056-24-2
- Ergosta-5,24(28)-diene-3,7,16-triol
Catalog No.:BCN5190
CAS No.:289054-34-8
- Z-D-Met-OH
Catalog No.:BCC2758
CAS No.:28862-80-8
- S-(-)-Carbidopa
Catalog No.:BCN8453
CAS No.:28860-95-9
- H-Asp(OBzl)-OBzl.TosOH
Catalog No.:BCC2886
CAS No.:2886-33 -1
- Cediranib (AZD217)
Catalog No.:BCC1121
CAS No.:288383-20-0
- (-)-dicentrine
Catalog No.:BCC8167
CAS No.:28832-07-7
- Lithospermic acid
Catalog No.:BCN5369
CAS No.:28831-65-4
- alpha-Asarone
Catalog No.:BCN3837
CAS No.:2883-98-9
- Denudanolide A
Catalog No.:BCN6522
CAS No.:288259-72-3
- Y-320
Catalog No.:BCC5202
CAS No.:288250-47-5
- Phlorigidoside B
Catalog No.:BCN5189
CAS No.:288248-46-4
- Fmoc-Cl
Catalog No.:BCC2802
CAS No.:28920-43-6
- Anodendrine
Catalog No.:BCN1956
CAS No.:28942-07-6
- Canertinib dihydrochloride
Catalog No.:BCC1449
CAS No.:289499-45-2
- Allo-Thr-OH
Catalog No.:BCC3101
CAS No.:28954-12-3
- Cassiachromone
Catalog No.:BCN5192
CAS No.:28955-30-8
- Oridonin
Catalog No.:BCN5953
CAS No.:28957-04-2
- Lasiodin
Catalog No.:BCN3387
CAS No.:28957-08-6
- Senicapoc
Catalog No.:BCC1943
CAS No.:289656-45-7
- Boc-HomoArg(NO2)-OH
Catalog No.:BCC2646
CAS No.:28968-64-1
- CB 300919
Catalog No.:BCC1456
CAS No.:289715-28-2
- Pectolinarin
Catalog No.:BCN1217
CAS No.:28978-02-1
- Persicoside
Catalog No.:BCN4780
CAS No.:28978-03-2
Fluoxetine Does Not Enhance Visual Perceptual Learning and Triazolam Specifically Impairs Learning Transfer.[Pubmed:27807412]
Front Hum Neurosci. 2016 Oct 19;10:532.
The selective serotonin reuptake inhibitor fluoxetine significantly enhances adult visual cortex plasticity within the rat. This effect is related to decreased gamma-aminobutyric acid (GABA) mediated inhibition and identifies fluoxetine as a potential agent for enhancing plasticity in the adult human brain. We tested the hypothesis that fluoxetine would enhance visual perceptual learning of a motion direction discrimination (MDD) task in humans. We also investigated (1) the effect of fluoxetine on visual and motor cortex excitability and (2) the impact of increased GABA mediated inhibition following a single dose of Triazolam on post-training MDD task performance. Within a double blind, placebo controlled design, 20 healthy adult participants completed a 19-day course of fluoxetine (n = 10, 20 mg per day) or placebo (n = 10). Participants were trained on the MDD task over the final 5 days of fluoxetine administration. Accuracy for the trained MDD stimulus and an untrained MDD stimulus configuration was assessed before and after training, after Triazolam and 1 week after Triazolam. Motor and visual cortex excitability were measured using transcranial magnetic stimulation. Fluoxetine did not enhance the magnitude or rate of perceptual learning and full transfer of learning to the untrained stimulus was observed for both groups. After training was complete, trazolam had no effect on trained task performance but significantly impaired untrained task performance. No consistent effects of fluoxetine on cortical excitability were observed. The results do not support the hypothesis that fluoxetine can enhance learning in humans. However, the specific effect of Triazolam on MDD task performance for the untrained stimulus suggests that learning and learning transfer rely on dissociable neural mechanisms.
Next-day residual effects of gabapentin, diphenhydramine, and triazolam on simulated driving performance in healthy volunteers: a phase 3, randomized, double-blind, placebo-controlled, crossover trial.[Pubmed:27018419]
Hum Psychopharmacol. 2016 May;31(3):217-26.
OBJECTIVE: Next-day residual effects of a nighttime dose of gabapentin 250 mg were evaluated on simulated driving performance in healthy participants in a randomized, placebo-controlled, double-blind, multicenter, four-period crossover study that included diphenhydramine citrate 76 mg and Triazolam 0.5 mg. METHODS: At treatment visits, participants (n = 59) were dosed at ~23:30, went to bed immediately, and awakened 6.5 h postdose for evaluation. The primary endpoint was the standard deviation of lateral position for the 100-km driving scenario. Additional measures of driving, sleepiness, and cognition were included. RESULTS: Study sensitivity was established with Triazolam, which demonstrated significant next-day impairment on all driving endpoints, relative to placebo (p < 0.001). Gabapentin demonstrated noninferiority to placebo on standard deviation of lateral position and speed deviation but not for lane excursions. Diphenhydramine citrate demonstrated significant impairment relative to gabapentin and placebo on speed deviation (p < 0.05). Other comparisons were either nonsignificant or statistically ineligible per planned, sequential comparisons. Secondary endpoints for sleepiness and cognitive performance were supportive of these conclusions. CONCLUSIONS: Together, these data suggest that low-dose gabapentin had no appreciable next-day effects on simulated driving performance or cognitive functioning. Copyright (c) 2016 John Wiley & Sons, Ltd.
Somnophilia and Sexual Abuse Using Vaginal Administration of Triazolam.[Pubmed:27122434]
J Forensic Sci. 2016 May;61(3):862-863.
Somnophilia is a rare paraphilia, a form of sexual fetishism which is characterized by the desire to have sex with an unconscious human object who is unable to respond. To the author's knowledge, this is the first case study concerning somnophilic sexual abuse associated with vaginal administration of Triazolam. The perpetrator video-recorded his sexual acts with two unconscious female victims with whom he also had normal sexual intercourse and who were unaware of his paraphilic activities. His Internet conversations with other persons whom he thought to be interested in somnophilic sex and his plans to kidnap a child were recorded by the police. It was evident that sex with an unconscious object played a specific fetishistic role for this man. He obviously used a combination of drugs mixed with alcoholic drinks to make his victims fall sleep and videotaped vaginal administration of Triazolam used to deepen the victim's unconscious state.